Literature DB >> 16538662

Inhibition of phospholipase C-beta1-mediated signaling by O-GlcNAc modification.

Yun-Hee Kim1, Minseok Song, Young-Seok Oh, Kyun Heo, Jung-Woong Choi, Ji-Man Park, Sun-Hee Kim, Seyoung Lim, H Moo Kwon, Sung Ho Ryu, Pann-Ghill Suh.   

Abstract

Here we report inhibition of phospholipase C-beta1 (PLC-beta1)-mediated signaling by post-translational glycosylation with beta-N-acetylglucosamine (O-GlcNAc modification). In C2C12 myoblasts, isoform-specific knock-down experiments using siRNA showed that activation of bradykinin (BK) receptor led to stimulation of PLC-beta1 and subsequent intracellular Ca2+ mobilization. In C2C12 myotubes, O-GlcNAc modification of PLC-beta1 was markedly enhanced in response to treatment with glucosamine (GlcNH2), an inhibitor of O-GlcNAase (PUGNAc) and hyperglycemia. This was associated with more than 50% inhibition of intracellular production of IP3 and Ca2+ mobilization in response to BK. Since the abundance of PLC-beta1 remained unchanged, these data suggest that O-GlcNAc modification of PLC-beta1 led to inhibition of its activity. Moreover, glucose uptake stimulated by BK was significantly blunted by treatment with PUGNAc. These data support the notion that O-GlcNAc modification negatively modulates the activity of PLC-beta1. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16538662     DOI: 10.1002/jcp.20609

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

Review 1.  Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system.

Authors:  Norbert Fülöp; Richard B Marchase; John C Chatham
Journal:  Cardiovasc Res       Date:  2006-07-29       Impact factor: 10.787

2.  Dynamic O-GlcNAcylation and its roles in the cellular stress response and homeostasis.

Authors:  Jennifer A Groves; Albert Lee; Gokben Yildirir; Natasha E Zachara
Journal:  Cell Stress Chaperones       Date:  2013-04-26       Impact factor: 3.667

Review 3.  Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease.

Authors:  Gerald W Hart; Chad Slawson; Genaro Ramirez-Correa; Olof Lagerlof
Journal:  Annu Rev Biochem       Date:  2011       Impact factor: 23.643

4.  Activated nuclear metabotropic glutamate receptor mGlu5 couples to nuclear Gq/11 proteins to generate inositol 1,4,5-trisphosphate-mediated nuclear Ca2+ release.

Authors:  Vikas Kumar; Yuh-Jiin I Jong; Karen L O'Malley
Journal:  J Biol Chem       Date:  2008-03-12       Impact factor: 5.157

5.  Sphingosine-1-phosphate promotes lymphangiogenesis by stimulating S1P1/Gi/PLC/Ca2+ signaling pathways.

Authors:  Chang Min Yoon; Bok Sil Hong; Hyung Geun Moon; Seyoung Lim; Pann-Ghill Suh; Yoon-Keun Kim; Chi-Bom Chae; Yong Song Gho
Journal:  Blood       Date:  2008-06-09       Impact factor: 22.113

6.  Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system.

Authors:  Boglarka Laczy; Bradford G Hill; Kai Wang; Andrew J Paterson; C Roger White; Dongqi Xing; Yiu-Fai Chen; Victor Darley-Usmar; Suzanne Oparil; John C Chatham
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-11-21       Impact factor: 4.733

7.  FGF23 Induction of O-Linked N-Acetylglucosamine Regulates IL-6 Secretion in Human Bronchial Epithelial Cells.

Authors:  Stefanie Krick; Eric Scott Helton; Samuel B Hutcheson; Scott Blumhof; Jaleesa M Garth; Rebecca S Denson; Rennan S Zaharias; Hannah Wickham; Jarrod W Barnes
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-27       Impact factor: 5.555

Review 8.  Role of O-linked N-acetylglucosamine (O-GlcNAc) modification of proteins in diabetic cardiovascular complications.

Authors:  John C Chatham; Martin E Young; Jianhua Zhang
Journal:  Curr Opin Pharmacol       Date:  2020-09-13       Impact factor: 4.768

Review 9.  Role of O-Linked N-Acetylglucosamine Protein Modification in Cellular (Patho)Physiology.

Authors:  John C Chatham; Jianhua Zhang; Adam R Wende
Journal:  Physiol Rev       Date:  2020-07-30       Impact factor: 37.312

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.